Loading company…
ViGeneron GmbH is a Munich biotech company developing AAV-based gene therapies for eye diseases.
Founded in 2017 and headquartered in Munich, Germany, ViGeneron GmbH develops gene therapies for ophthalmic diseases, including inherited retinal disorders, using three proprietary adeno-associated virus (AAV) platforms. Revenue comes from partnerships with biopharmaceutical companies through upfront, milestone, and royalty payments. In November 2019, the company raised an undisclosed amount in its first Series A round, led by Sequoia Capital China and WuXi AppTec Group.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in